1. High-Performance Interaction-Based Simulation of Gut Immunopathologies with ENteric Immunity Simulator (ENISI)
- Author
-
Dawen Xie, Keith R. Bisset, Madhav V. Marathe, Stefan Hoops, Raquel Hontecillas, Yongguo Mei, Stephen Eubank, Maksudul Alam, Katherine Wendelsdorf, Adria Carbo, Jae-Seung Yeom, and Josep Bassaganya-Riera
- Subjects
Mucosal Immune Responses ,biology ,Computer science ,Microorganism ,Gastrointestinal pathogens ,Helicobacter pylori ,Antimicrobial ,medicine.disease ,biology.organism_classification ,Inflammatory bowel disease ,Vaccination ,Immune system ,Immunity ,Infectious disease (medical specialty) ,Enteric disease ,Bacterial virulence ,Computational immunology ,medicine ,Simulation - Abstract
Here we present the ENteric Immunity Simulator (ENISI), a modeling system for the inflammatory and regulatory immune pathways triggered by microbe-immune cell interactions in the gut. With ENISI, immunologists and infectious disease experts can test and generate hypotheses for enteric disease pathology and propose interventions through experimental infection of an in silico gut. ENISI is an agent based simulator, in which individual cells move through the simulated tissues, and engage in context-dependent interactions with the other cells with which they are in contact. The scale of ENISI is unprecedented in this domain, with the ability to simulate $10^7$ cells for 250 simulated days on 576 cores in one and a half hours, with the potential to scale to even larger hardware and problem sizes. In this paper we describe the ENISI simulator for modeling mucosal immune responses to gastrointestinal pathogens. We then demonstrate the utility of ENISI by recreating an experimental infection of a mouse with Helicobacter pylori 26695. The results identify specific processes by which bacterial virulence factors do and do not contribute to pathogenesis associated with H. pylori strain 26695. These modeling results inform general intervention strategies by indicating immunomodulatory mechanisms such as those used in inflammatory bowel disease may be more appropriate therapeutically than directly targeting specific microbial populations through vaccination or by using antimicrobials.
- Published
- 2012
- Full Text
- View/download PDF